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ABSTRACT 
Hepatocellular carcinoma (HCC), the most common primary liver tumor, is the 
fifth most common human malignancy and the second leading cause of cancer death. 
Owing to the difficulty in early diagnosis and lack of effective chemo/radiotherapy, 
the five-year overall survival rate remains poor in advanced HCC patients. 
Dysregulated growth factors signaling pathways play pivotal roles in controlling 
hepatocellular carcinoma (HCC) malignancy phenotype and progression. 
Nevertheless, the precise oncogenic mechanisms in certain tumor suppressor genes 
(TSG) transcriptional regulation by growth factors is poorly understood. Here, we 
report a novel pathway about growth factors which worked via de novo DNA 
methylation and TSG silencing by up-regulation of DNMT1. As one epigenetic 
mechanism, DNA methylation catalyzed by DNA methyltransferases (DNMTs) cause 
changes in chromatin structure, DNA conformation, DNA stability, and the patterns 
of DNA-protein interaction. DNA hypermethylation leading to transcriptional 
silencing of a relatively large TSG. The over-expression of DNMTs has been reported 
in various cancers.And it is already recognized that many risk factors for HCC may 
up-regulate expression of the DNMTs, such as HBV encoded protein X (HBx). 
however, to date there is little evidence on the delicate mechanism of DNMTs 
over-expression in HCC. 
Firstly, we found a direct evidence that activation of IGFs/IGF1Rβ axis 
up-regulate DNMT1 expression via AKT/beta-transducin repeats-containing proteins 
(βTrCP) mediated ubiquitin-proteasome pathway in HCC. We found that IGF1 
phosphorylates and inactives GSK3β, which recruit βTrCP to result in degradation of 
substrate protein DNMT1 through ubiquitin-proteasome pathway. Secondly, we gave 
a comprehensive study for biological function of DNMTs in liver cancer cell. Finally 
the extensive genome-wide DNA methylation in CpG island of target gene were 
determined with the high co-localization of DNMT1 and DNMT3B by using 
ChIP-chip coupled with CpG island microarray analysis. In ChIP and MS-PCR assays, 
we demonstrated that specifically located DNMTs on DLC1 and CHD5 gene 
promoter loci were associated with enhanced CpG hypermethylation, which is 
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Taken together, our findings uncover a previousely unknown epigenetic 
mechanism for growth factor repress certain TSG transcription partly through DNA 
methylation, and also present a mechanistic and prognostic significance of aberrant 
DNMT1 expression in HCC. 
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图 1-1  中国男性肝癌患者死亡率分布图[1] 


















2.1 DNA 甲基化修饰 
人类基因组由四种核苷组成, 它们是胞嘧啶核苷(Cytosine, C)、胸腺嘧啶核苷
(T hymine, T)、鸟嘌呤核苷( Guanosine, G)、腺嘌呤核苷( Adenosine,A)。其中, C
与G在一起出现称为CpG, 中间的p指C与G之间的磷酸键。CpG 在人类基因组中
出现的频率只有0.18% , 远远低于预期频率4%。但在染色体的某些区域, C+G的
含量及CpG的频率要高于基因组的整体水平。当C+G的含量超过50% , CpG 出现
的实际频率与预期频率之比达到0.16%, 碱基对长度达到200bp时, 这一区域被称
为CpG岛[5]。CpG岛出现于所有看家基因( house keeping gene) 及很多组织特异性
基因的5’端, 并可延伸至基因的第一个或多个外显子和内含子。有些CpG岛也可
出现于基因的编码区甚至下游3’端[6]。DNA甲基化是在 DNA甲基转移酶 ( DNA 
methylt ransferase , DNMT)的作用下 DNA序列上CpG岛的二核苷酸 5’端胞嘧啶
转变为 5’甲基胞嘧啶 ( 5’methyl cy tosine , 5mC)。位于CpG岛中的胞嘧啶残基在
其第5号碳原子上的甲基化是一种常见的DNA修饰现象。DNA甲基化是引入甲基




维持甲基化酶(maintenance methylase), 维持DNA甲基化状态, 人类的DNMT1, 
定位在人染色体的19p13.2上, 鼠和人的DNMT1有78%的同源性。DNMT1由1620
个氨基酸组成, C末端为酶反应区域, 属于相对保守区; N末端是酶的调节区域, 
该区域与DNMT1在胞浆与胞核间的转移、细胞周期S期时DNMT1与DNA复制叉
的结合, 以及部分抑癌基因制新发甲基化的发生等有关[8]。目前认为DNMT2没有






























甲基化常与基因活化的标志DN aseI高敏感区( hypersensitive site , HS site)同时出
现。 
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